NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ:ADMS) between August 8, 2017, and September 30, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

If you purchased Adamas securities, and/or would like to discuss your legal rights and options please visit Adamas Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, it is alleged that Defendants made materially false and misleading statements about: (1) managed care's acceptance of GOCOVRI; (2) the breadth of insurer coverage for GOCOVRI prescriptions; and (3) the impact of the Company's commercialization efforts. In addition, it is alleged that Defendants failed to disclose: (1) that health insurers were excluding GOCOVRI from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) that the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) that, as a result of the foregoing, the Company's financial statements and Defendants' statements about Adamas's business, operations, and prospects, were materially false and misleading at all relevant times.

After the market closed on March 4, 2019, during Adamas's Q4 2018 conference call with investors, Adamas walked back its previous prescription growth estimates for GOCOVRI, warned of a continued slow-down in GOCOVRI prescriptions, and refused to make further predictions about GOCOVRI's ability to achieve a sizeable market share. On this news, Adamas's stock fell $3.99 per share, or 32.84%, to close at $8.16 per share on March 5, 2019.

On September 30, 2019, Bank of America/Merrill Lynch analyst Tazeen Ahmad lowered its rating for Adamas shares to "Underperform" noting "existing overhangs for ADMS: (1) Gocovri coverage: a number of national formularies exclude Gocovri. We expect reimbursement hurdles in MSWI space especially with generic Ampyra launch." On this news, Adamas shares fell a further 42.83% from $7.05 per share on September 26 to $4.03 by October 3, 2019.

If you purchased Adamas securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/adamaspharmaceuticalsinc-adms-shareholder-class-action-lawsuit-stock-fraud-229/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

If you wish to serve as lead plaintiff, you must move the Court no later than February 10, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

SOURCE: Bernstein Liebhard LLP

ReleaseID: 570469

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Conagra Brands, Inc. ("Conagra" or "the Company") (NYSE:CAG) for violations of securities laws.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
Cell: 424-303-1964
info@schallfirm.com
www.schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570456

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. ("Adamas" or "the Company") (NASDAQ:ADMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between August 8, 2017 and September 30, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Adamas suffered from insurers excluding GOCOVRI from their coverage or requiring patients to try other therapies first. The rapid increase in doctors prescribing GOCOVRI to patients was not based on the drug's effectiveness. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Adamas, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570444

Please refer to attachments for content

ReleaseID: 570476

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fiat Chrysler Automobiles N.V. ("Fiat Chrysler" or "the Company") (NYSE:FCAU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 26, 2016 and November 20, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 31, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Fiat engaged in a bribery scheme designed to gain favorable terms from labor unions for its collective bargaining agreements. Executives at the top levels of management for the Company were aware of the schemes. Based on the facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Fiat, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570445

LOS ANGELES, CA / ACCESSWIRE / December 16, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against PG&E Corporation ("PG&E" or ''the Company'') (NYSE:PCG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between December 11, 2018 and October 11, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before December 24, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. PG&E's supposedly enhanced protocols for wildfire prevention and safety were not sufficient to solve the very problems they were designed to mitigate. The Company was completely unprepared for rolling power cuts to minimize the risk of wildfires. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about PG&E, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 570450

VANCOUVER, BC / ACCESSWIRE / December 16, 2019 / Maple Leaf Short Duration 2020 Flow-Through Limited Partnership (the "Partnership") is pleased to announce that it has filed a preliminary prospectus (the "Prospectus") dated December 12, 2019 with the securities commissions or similar authorities in each of the Provinces and Territories of Canada relating to the initial public offering of units of the Partnership.

Partnership Objectives & Benefits – National Class Units

The Partnership is designed to provide holders of National Class Units ("National Class Limited Partners") with an investment in a diversified portfolio of Flow-Through Shares of Resource Companies incurring Eligible Expenditures (as those terms are defined in the Prospectus) across Canada with a view to maximizing the tax benefits of an investment in National Class Units and achieving capital appreciation and/or income for National Class Limited Partners. National Class Limited Partners must be residents of Canada or liable to pay Canadian income tax.

Investors are expected to receive tax deductions for 2020 of approximately 100% of the amount invested based on and subject to certain conditions as set forth in the Prospectus.

Partnership Objectives & Benefits – Québec Class Units

The Partnership is designed to provide holders of Québec Class Units ("Québec Class Limited Partners") with an investment in a diversified portfolio of Flow-Through Shares of Resource Companies incurring Eligible Expenditures principally in the Province of Québec with a view to maximizing the tax benefits of an investment in Québec Class Units and achieving capital appreciation and/or income for Québec Class Limited Partners. Québec Class Units are most suitable for investors who reside in the Province Québec or are liable to pay income tax in Québec.

Investors are expected to receive tax deductions for 2020 of up to approximately 131% of the amount invested based on and subject to certain conditions as set forth in the Prospectus.

Liquidity Event

The investment portfolios of both the National and Québec Class Units will be actively managed in such a way as to preserve the ability to undertake a future liquidity event, such as a rollover into a mutual fund corporation.

The Syndicate

The syndicate of agents for the offering is being led by Scotiabank and includes National Bank Financial Inc., CIBC World Markets Inc., BMO Nesbitt Burns Inc., Industrial Alliance Securities Inc., Stifel Nicolaus Canada Inc., Canaccord Genuity Corp., Desjardins Securities Inc., Echelon Wealth Partners Inc., Manulife Securities Incorporated, Raymond James Ltd. and Laurentian Bank Securities Inc.

A copy of the Prospectus can be obtained from any agent.

Offering Jurisdictions

Each of the Provinces and Territories of Canada.

FOR FURTHER INFORMATION, PLEASE CONTACT

Hugh Cartwright, Chairman

MAPLE LEAF FLOW-THROUGH PROGRAMS

Tel: 1-866-688-5750

Email: info@mapleleaffunds.ca Web: www.MapleLeafFunds.ca

www.MapleLeafFunds.ca

A preliminary prospectus dated December 12, 2019 relating to these securities has been filed with the securities commissions or similar authorities in each of the Provinces and Territories of Canada but has not yet become final for the purpose of distribution to the public. This release shall not constitute an offer to sell or the solicitation of any offer to buy the securities. This release is provided for information purposes only. Commissions, trailing commissions, management fees and expenses all may be associated with investment funds. Please read the Prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. Capitalized terms not defined herein have the meanings set forth in the Prospectus.

SOURCE: 

ReleaseID: 570457

BALA CYNWYD, PA / ACCESSWIRE / December 16, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

ARQULE, INC. (NasdaqGS:ARQL)

Under the terms of the agreement, ArQule shareholders will receive only $20.00 for each share of ArQule common stock owned. The investigation concerns whether the ArQule Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Merck is underpaying for the Company. For example, ArQule's lead new drug candidate under development, called ARQ 531, is a potential treatment of B-cell malignancies including relapsed or refractory chronic lymphocytic leukemia. Merck's President commented, "ArQule's focus on precision medicine has yielded multiple clinical-stage oral kinase inhibitors that have novel and important properties, …. This acquisition strengthens Merck's pipeline with the addition of these strategic assets."

Additional information can be found at http://www.brodskysmith.com/cases/arqule-inc-nasdaqgs-arql/, or call 877-534-2590. No cost or obligation to you.

AUDENTES THERAPEUTICS, INC. (NasdaqGS:BOLD)

Under the terms of the agreement, Audentes shareholders will receive only $60.00 for each share of Audentes common stock owned. The investigation concerns whether the Audentes Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Astellas Pharma, Inc.is underpaying for the Company. The transaction may undervalue the Company. For example, the merger will provide Astellas with Audentes robust pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).

Additional information can be found at http://www.brodskysmith.com/cases/audentes-therapeutics-inc-nasdaqgs-bold/, or call 877-534-2590. No cost or obligation to you.

KEMET CORPORATION (NYSE:KEM)

Under the terms of the agreement, KEMET shareholders will receive only $27.20 for each share of KEMET common stock owned. The investigation concerns whether the KEMET Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Yageo Corporation is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many KEMET shareholders. For example, an analyst following the stock has set a price target of $29.00.

Additional information can be found at http://www.brodskysmith.com/cases/kemet-corporation-nyse-kem/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 570425

BALA CYNWYD, PA / ACCESSWIRE / December 16, 2019 / Brodsky & Smith, LLC reminds investors of investigations it is conducting regarding the following companies for possible breaches of fiduciary duty and other violations of federal and state law with respect to proposed acquisition transactions. If you own shares of any of the below-referenced stocks and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, or calling toll free 877-534-2590. There is no cost or financial obligation to you.

INSTRUCTURE, INC. (NYSE:INST)

Under the terms of the agreement, Instructure shareholders will receive only $47.60 for each share of Instructure stock owned. The investigation concerns whether the Instructure Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Thoma Bravo is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Instructure shareholders. For example, the stock was trading over $53 a share in November 2019 and at least one analyst following the Company has set a price target of $56.00

Additional information can be found at http://www.brodskysmith.com/cases/instructure-inc-nyseinst/, or call 877-534-2590. No cost or obligation to you.

TIFFANY & CO. (NYSE:TIF)

Under the terms of the agreement, Tiffany shareholders will receive only $135.00 for each share of Tiffany common stock owned. The investigation concerns whether the Tiffany Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether LVMH is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many Tiffany shareholders. For example, at least one analyst following the Company has set a price target of $160.00.

Additional information can be found at http://www.brodskysmith.com/cases/tiffany-co-nyse-tif/, or call 877-534-2590. No cost or obligation to you.

TD AMERITRADE (Nasdaq:AMTD)

Under the terms of the agreement, TD Ameritrade shareholders will receive only 1.0837 shares of Charles Schwab stock for each share of TD Ameritrade common stock owned. This exchange ratio implied a deal price of $52.23 as of the last day of trading before the announcement. The investigation concerns whether the TD Ameritrade Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether Charles Schwab is underpaying for the Company. The transaction may undervalue the Company and would result in a substantial loss for many TD Ameritrade shareholders. For example, at least one analyst following the Company has set a price target of $60.00. Additionally, the implied deal price is well-below the 52-week high of $57.88.

Additional information can be found at http://www.brodskysmith.com/cases/td-ameritrade-holding-corporation-nasdaqgs-amtd/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 570420

NEW YORK, NY / ACCESSWIRE / December 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ: ADMS) Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Adamas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 4, 2019, during a conference call with investors, Adamas walked back its previous prescription growth estimates for its primary product, Gocovri, warned of a continued slow-down in Gocovri prescriptions, and refused to make further predictions about Gocovri's ability to achieve a sizeable market share.

On this news, Adamas's stock price fell $3.99 per share, or 32.4%, to close at $8.16 per share on March 5, 2019.

Then, on September 30, 2019, a Bank of America/Merrill Lynch analyst lowered its rating for Adamas stock to "Underperform," noting "existing overhangs for ADMS: (1) Gocovri coverage: a number of national formularies exclude Gocovri. We expect reimbursement hurdles in [multiple sclerosis walking impairment] space especially with generic Ampyra launch."

On this news, Adamas's stock price fell $1.55 per share, or 23.26%, to close at $5.12 per share on September 30, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

ReleaseID: 570462